PRECLINICAL
PHASE 1
PHASE 2
PHASE 3

RSLV-132

Sjögren’s Syndrome
Lupus (SLE)

RSLV-621

Lupus (SLE)

Bi-Specific Nuclease Platform

Lupus nephritis

RSLV-132

RSLV-132, our lead product candidate, is a novel compound that eliminates inflammatory nucleic acids, which are known to accumulate in lupus and Sjögren’s syndrome patients and cause chronic inflammation.

RSLV-621

RSLV-621, is an interferon trap which binds to type I and II interferons and prevents their pro-inflammatory activity. This preclinical asset will be tested in lupus, an autoimmune disease where increases in interferon gene expression are found in the majority of patients.

Bi-Specific Nuclease Platform

This nuclease platform will include human Fc fusion proteins consisting of both RNase and DNase. Our preclinical asset, RSLV-133, will be tested in lupus nephritis, an autoimmune disease in which both RNA and DNA contribute to inflammation causing kidney damage.